Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 10 Similar Profiles
HIV Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Hepacivirus Medicine & Life Sciences
Population Medicine & Life Sciences
Infection Medicine & Life Sciences
HIV-1 Medicine & Life Sciences
Hepatitis C Medicine & Life Sciences
Virus Diseases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2018 2019

Research Output 1998 2017

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

Cunningham, E. B. , Hajarizadeh, B. , Dalgard, O. , Amin, J. , Hellard, M. , Foster, G. R. , Bruggmann, P. , Conway, B. , Backmund, M. , Robaeys, G. , Swan, T. , Marks, P. S. , Quiene, S. , Applegate, T. L. , Weltman, M. , Shaw, D. , Dunlop, A. , Bruneau, J. , Midgard, H. , Bourgeois, S. & 4 others Thurnheer, M. C., Dore, G. J., Grebely, J. & on behalf of the ACTIVATE Study Group 13 Jun 2017 In : BMC Infectious Diseases. 17, 1, p. 1-12 12 p., 420

Research output: Research - peer-reviewArticle

Open Access

Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption

Lee, W. S., Kristensen, A. B., Rasmussen, T. A., Tolstrup, M., Østergaard, L., Søgaard, O. S., Wines, B. D., Mark Hogarth, P., Reynaldi, A., Davenport, M. P., Emery, S., Amin, J., Cooper, D. A., Kan, V. L., Fox, J., Gruell, H., Parsons, M. S. & Kent, S. J. 1 Aug 2017 In : Journal of Virology. 91, 15, p. 1-13 13 p., e00603-17

Research output: Research - peer-reviewArticle

HIV Antibodies
Human immunodeficiency virus 1

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

Boyd, M. A., Amin, J., Mallon, P. W. G., Kumarasamy, N., Lombaard, J., Wood, R., Chetchotisakd, P., Phanuphak, P., Mohapi, L., Azwa, I., Belloso, W. H., Molina, J. M., Hoy, J., Moore, C. L., Emery, S., Cooper, D. A. & SECOND-LINE Study Group 1 Jan 2017 In : The Lancet HIV. 4, 1, p. e13-e20 8 p.

Research output: Research - peer-reviewArticle

Body Composition

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: the ACTIVATE study

Midgard, H. , Hajarizadeh, B. , Cunningham, E. B. , Conway, B. , Backmund, M. , Bruggmann, P. , Bruneau, J. , Bourgeois, S. , Dunlop, A. , Foster, G. R. , Hellard, M. , Robaeys, G. , Thurnheer, M. C. , Weltman, M. , Amin, J. , Marks, P. S. , Quiene, S. , Dore, G. J. , Dalgard, O. , Grebely, J. & 1 others ACTIVATE Study Group Sep 2017 In : International Journal of Drug Policy. 47, p. 230-238 9 p.

Research output: Research - peer-reviewArticle

Virus Diseases
Pharmaceutical Preparations

Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment

Hajarizadeh, B., Grebely, J., McManus, H., Estes, C., Razavi, H., Gray, R. T., Alavi, M., Amin, J., McGregor, S., Sievert, W., Thompson, A. & Dore, G. J. 1 Jan 2017 In : Journal of Gastroenterology and Hepatology (Australia). 32, 1, p. 229-236 8 p.

Research output: Research - peer-reviewArticle

Chronic Hepatitis C
Virus Diseases